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The nuclear receptor, NR1C2 or peroxisome proliferator-activated receptor (PPAR)-δ, is ubiquitously expressed and important
for placental development, fatty acid metabolism, wound healing, inﬂammation, and tumour development. PPARδ has been
hypothesized to function as both a ligand activated transcription factor and a repressor of transcription in the absence of agonist.
In this paper, treatment of mice conditionally expressing human PPARδ with GW501516 resulted in a marked loss in body weight
thatwasnotevidentinnontransgenicanimalsoranimalsexpressingadominantnegativederivativeofPPARδ.Expressionofeither
functional or dominant negative hPPARδ blocked bezaﬁbrate-induced PPARα-dependent hepatomegaly and blocked the eﬀect of
bezaﬁbrate on the transcription of PPARα target genes. These data demonstrate, for the ﬁrst time, that PPARδ could inhibit the
activation of PPARα in vivo and provide novel models for the investigation of the role of PPARδ in pathophysiology.
1.Introduction
There are three PPAR isoforms, PPARα, β/δ (herein referred
to as δ), and γ.P P A R α is found in tissues with a high
rate of fatty acid catabolism where when agonist bound it
activates the expression of genes involved in peroxisomal
β-oxidation and mitochondrial β-a n dω-oxidation and
plays an important role in systemic fat catabolism, in the
generation of ketone bodies and stimulating gluconeoge-
nesis [1, 2]. Fibrate drugs cause PPARα-dependent liver
peroxisome proliferation, hepatomegaly, and subsequently
hepatocarcinoma when fed to rodents [2, 3]. Fibrate drugs
are used successfully in the clinic to treat hyperlipidaemia
and do not cause liver problems, most probably due to the
lower level of PPARα in human liver [4, 5].
There are two forms of PPARγ,( γ1a n dγ2, with diﬀering
amino termini). PPARγ is important for fatty acid and
triglyceride anabolism and storage and essential for the
diﬀerentiation of adipocytes [2].
PPARδ is the least known isoform in terms of biological
function and the most abundant PPAR isoform in all
tissues except liver and adipose tissue in rodents. PPARδ is
downregulated in liver and kidney in response to fasting [6].
In all tissues examined, PPARδ protein was predominantly
localised in the nucleus and could be immunoprecipitated
with RXRα [7]. pparδ−/− mice have impaired placental
function leading to viability problems [8–10]. Surviving
knockouts were leaner and had reduced adipose stores,
b u tt h i sd o e sn o ta p p e a rt ob ead i r e c te ﬀect of PPARδ,
since adipose-speciﬁc pparδ−/− mice did not show the same
phenotype [8]. PPARδ knockouts also showed increased
keratinocyte proliferation in response to topical application
of tetradecanoylphorbol acetate [9, 10].
PPARδ has been shown to play an important role in
cellular diﬀerentiation [11–13] and in regulating energy
homeostasis [8, 14]. Mice generated with PPARδ constitu-
tively active in adipocytes were found to be lean, and leptin
receptor mutant mice showed improved metabolic activity2 PPAR Research
and reduced fat deposits when fed GW501516 (a PPARδ-
speciﬁc agonist) [15]. Muscle-speciﬁc PPARδ overexpression
resulted in a net increase of muscle ﬁbres with an oxidative
metabolic phenotype with a concomitant decrease in body
fat [16]. Comparably, mice with a cardio-restricted deletion
of PPARδ showed decreased basal myocardial fatty acid
oxidation followed by chronic lipid accumulation in the
heart that led to cardiac hypertrophy and congestive heart
failure [17].
The involvement of PPARδ in cancer promotion in var-
ious organs is clear; however, there is controversy about
whether ligand activation of PPARδ is pro- or anti-
tumourigenic. Following initiation, increased breast tumour
development was evident in animals fed with GW501516
[18]. In animal models of colorectal cancer, PPARδ has been
shown to both inhibit and promote the growth of intestinal
polyps [8, 19, 20].
One study has shown that PPARδ was able to attract
transcriptional corepressors and when bound to DNA in the
absence of a PPARδ agonist more eﬀectively than PPARα
or PPARγ [21]. On the other hand, treatment of wild-type
adipocytes with troglitazone, a potent PPARγ ligand, caused
upregulation in PPARγ activity as measured by adipocyte
diﬀerentiation and lipid accumulation assays. This eﬀect was
alsoalmostentirelypreservedinPPARδ-nulladipocytes[22];
however, in another study, authors conclude that PPARδ
suppressed PPARγ activity, but downregulation of PPARδ
expression did not increase PPARγ expression levels [23]. A
diﬀerent study has shown that PPARδ is able to repress both
PPARα and γ-dependent gene expression in vitro [24]. Since
PPARδ is the predominant PPAR isoform in many tissues
[6], it was proposed that PPARδ could act as a PPRE gateway
receptor[24].However,deletionofthecarboxyterminalexon
of PPARδ did not result in increased expression of PPARα
target genes in liver [25].
With confusing and opposing results being observed
using knockout and drug models, we decided to take an
alternative route to provide genetic models for both gain
and loss of function of PPARδ. We show that we can control
expression of hPPARδ and hPPARδΔAF2 (a dominant neg-
ative derivative lacking the 11 carboxy-terminal aminoacid
residues [26, 27]) in transgenic animals and that we can
modulate PPAR-dependent gene expression in liver as well as
thehepatomegalyassociatedwithactivationofPPARα.These
new mouse models for studying PPARδ biology should thus
beusefulinresolvingsomeoftheuncertaintiesregardingthis
receptor.
2. Results
2.1. Conditional Expression of hPPARδ and hPPARδΔAF2 in
Transgenic Mice. Two mouse lines were generated that con-
ditionally express human PPARδ and a dominant negative
derivative thereof, hPPARδΔAF2 (Figure 1). This approach
allows for the manipulation of the levels of PPRE signaling
through the conditional production of human PPARδ and
a dominant negative derivative, hPPARδAF2, in transgenic
mice. The Cyp1a1 gene is tightly regulated in vivo and
its expression is wholly dependent on the arylhydrocarbon
receptor (AhR), functioning as a heterodimer with the AhR
nucleartranslocator,Arnt,thatbindsthexenobioticresponse
element enhancer sequence in the regulatory 5  UTR of
the Cyp1a1 gene. The promoter of the rat Cyp1a1 gene has
beenusedtoconditionallyexpressseveralgenesintransgenic
models [28–30]. The expression of genes under the control
of the Cyp1a1 promoter is achieved by the administering of
compounds that activate XRE-driven gene expression.
I3C, found in cruciferous vegetables, is converted to
polyaromatic indolic compounds in the acid environment
of the stomach and produces a potent and dose-dependent
activation of XRE driven gene expression [31]. Feeding
transgenic mice with a diet supplemented with I3C (0.5%
(w/w)) or (0.25% (w/w)) resulted in a similar induction
of both hPPARδ and hPPARδΔAF2 transgenes in these
animals (data not shown). Based on this result, we fed
nontransgenic, hPPARδ and hPPARδΔAF2 transgenic mice
either on control diet or a diet supplemented with I3C
(0.25%(w/w))for5daysandexaminedtransgeneexpression
inarangeoforgans(Figure 2).hPPARδ mRNAfromliversof
mice fed control diet was virtually undetectable, but hPPARδ
message increased approximately 30,000-fold upon feeding
I3C (0.25% (w/w)) for 5 days (Figure 2(a)). By contrast,
hPPARδΔAF2 animals on control diet had approximately
10-fold greater basal expression of the transgene than did
the hPPARδ mice on the same diet. However, when these
animals were fed on a diet containing I3C, the hPPARδΔAF2
transgene expression in the liver increased (2900-fold) to
levels similar to that of animals expressing the hPPARδ
transgene (Figure 2(a)). Although I3C induced mRNA levels
of both the hPPARδ and hPPARδΔAF2 transgenes to similar
levels in these mice, the corresponding protein expression
in the livers of these mice diﬀered. Using a monoclonal
antibody raised against hPPARδ, animals expressing the
hPPARδ transgene showed a robust increase in hPPARδ
protein in their livers when fed on an I3C-supplemented diet
compared to those on control diet (Figure 2(b)). When liver
hPPARδΔAF2 protein was examined in mice expressing this
t r a n s g e n e ,t h e r ew a sf o u n dt ob eam u c hl e s sr o b u s ti n c r e a s e
in protein expression (Figure 2(b), see arrow). It is possible
that hPPARδΔAF2-truncated protein may be less stable in
the livers of these animals than the human full length form.
Low basal expression of both hPPARδ and hPPARδΔAF2
mRNA was also observed in the adipose, brain, kidney, large
intestine, muscle, ovary, and testis of animals on control diet
with no signiﬁcant induction of message by I3C observed
in the brain, adipose, breast, heart, kidney, stomach, spleen,
lung, muscle, ovary, or testis of mice harbouring either
transgene. The large intestine showed the largest induction
of both transgenes in response to I3C treatment. A greater
basal expression of hPPARδ transcript was seen in breast,
heart, small intestine, and stomach. These organs showed an
increase in hPPARδ expression upon feeding animals with
an I3C-supplemented diet, but this increase was signiﬁcant
only in small intestine, P = 0.0007 and P = 0.005 for
hPPARδ and hPPARδΔAF2, respectively. Lung and muscle
showed a very diﬀerent pattern of expression from the other
tissues in that basal expression of hPPARδ was low and
not inducible by I3C dietary supplementation. In lung, thePPAR Research 3
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Figure 1: Graphic depicting the generation of mice conditionally expressing hPPARδ and hPPARδΔAF2 transgenes. Mice harbouring
transgenes, encoding the coding sequence of hPPARδ or hPPARδΔAF2 fused to the rat Cyp1a1 gene promoter and oﬀering tight control
of XRE enhancer driven transgene expression.
basal expression of hPPARδΔAF2 was high and induction by
I3C observed but not signiﬁcant. In muscle, however, basal
expression of hPPARδΔAF2 was low but induced by I3C in
the diet, P = 0.033. hPPARδ is known to be expressed in the
sebaceous gland of the skin, and is induced upon feeding I3C
in keratinocytes of hPPARδ transgenic mice [32].
2.2. Induction and Activation of hPPARδ Causes Body Weight
Loss. PPARδ activation is known to produce favorable
metaboliceﬀectsthatincludeweightlosswithincreasedmet-
abolic rate in skeletal muscle, improved exercise endurance
and insulin sensitivity [15, 33]. To investigate the role of
activating hPPARδ and hPPARδΔAF2 on body weight, mice
were fed either on normal diet supplemented with I3C
(0.25% (w/w)) (I3C diet) or on an I3C diet supplemented
with GW501516 (0.005% (w/w)) for 14 days. There was no
diﬀerence in the weights of either nontransgenic, hPPARδ
or hPPARδΔAF2 transgenic mice fed on I3C diet (Table 1
and Figure 3(a)). In nontransgenic mice, there was a small
although signiﬁcant reduction in body weight when mice
were given I3C diet containing GW501516 likely as a
response of endogenous PPARδ activation by the ligand
(Table 1 and Figure 3(a)). In animals carrying hPPARδ
placed on the GW501516 diet, there was a marked reduction
in body weight (direct weight diﬀerence (P = 0.017) and
percentage of body weight (P = 0.008)) over the two-
week period that was completely absent in nontransgenic
animals or animals expressing hPPARδΔAF2 (Table 1 and
Figure 3(a)).
2.3. GW501516-Dependent Activation of Gene Expression
Is Abolished, or Reversed, by hPPARδΔAF2. hPPARδΔAF2
has been shown to act in a dominant negative fashion
in vitro.T h i se ﬀect was augmented by the addition of a
PPARδ agonist [26]. To examine the eﬀect of conditionally
expressing hPPARδΔAF2 on PPARδ target gene expression,
animals were fed on a diet containing either I3C (0.25%
(w/w)) only or on a diet containing I3C and GW5015164 PPAR Research
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Figure 2: Mice conditionally express hPPARδ or hPPARδΔAF2 transgenes in response to feeding I3C. Animals (n = 3p e rg r o u p ,1 0
weeks old, mixed male and female) were placed either on control diet or a diet containing I3C (0.25% (w/w)) for 5 days. (a) hPPARδ
and hPPARδΔAF2 exhibit low basal mRNA expression (open bars) and highly inducible I3C-dependent expression (black bars) in mouse
liver. (b) hPPARδ and hPPARδΔAF2 protein is expressed in livers in response to dietary supplementation with I3C. (c) hPPARδ (hδ)
and hPPARδΔAF2 (DN) mRNA expression in various mouse organs in response to normal diet (open bars) and I3C-supplemented diet
(black bars). Statistical signiﬁcance where indicated was analysed using Mann-Whitney nonparametric test in GraphPad Prism version 5.0c,
(GraphPad Software, San Diego, CA, USA). Signiﬁcance is portrayed as (∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.001).
(0.25% (w/w) and 0.0025% (w/w), resp.) for 2 weeks prior
to liver and muscle tissue being harvested and analyzed for
relative mRNA expression levels of Acox1, Adrp,a n dm o u s e
PPARδ (Figures 3(b)–3(f)).
Acox1, a known PPARδ target encoding the ﬁrst enzyme
of the fatty acid β-oxidation pathway, was upregulated in
muscle (P = 0.016) but not in liver of nontransgenic animals
fed a diet containing GW501516 (Figures 3(b) and 3(c)).
This muscle upregulation of Acox1 is most likely attributable
to activation of endogenous mPPARδ. We found, however,
that the hPPARδ transgene is required for up-regulation of
Acox1 mRNA in liver (P = 0.036), indicating the presence
of a functional hPPARδ protein. Up-regulation of muscle
Acox 1 in response to GW501516 was also observed in
hPPARδ transgenic animals (P = 0.015) (Figure 3(c)).
hPPARδ, however, is not likely to be involved in this
response as expression of this transgene was not seen in
muscle of hPPARδ-transgenic mice when administered I3C
in the diet (Figure 2(c)), and a similar level of induction
of Acox1 w a ss e e ni nn o n t r a n s g e n i cm i c e( Figure 3(c)). In
contrast, hPPARδΔAF2 was shown to be inducible in both
liver and muscle of hPPARδΔAF2 transgenic mice by I3C
(Figure 2(c)). The GW501516-dependent up-regulation of
Acox1 in both liver and muscle was completely inhibited inPPAR Research 5
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Figure 3:MiceexpressingfunctionalhPPARδ andhPPARδΔAF2protein.Animals(n = 5pergroup,12weeksold,mixedmalesandfemales)
were placed on a diet containing I3C (0.25% (w/w)) (open bars) or a diet containing I3C (0.25% (w/w)) and GW501516 (0.0025% (w/w))
(black bars) for 14 days. (a) body weight of nontransgenic (Non-Tg), hPPARδ and hPPARδΔAF2 transgenic mice expressed as a percentage
ofinitialbodyweight.(b–f)mRNAexpressionof Acox1 inliver (b),muscle(c),mRNAexpressionof Adrp inliver (d),muscle(e),andmouse
endogenous PPARδ (f) following treatments outlined above. Statistical signiﬁcance (∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.001) where indicated
was analysed using Mann-Whitney non-parametric test in GraphPad Prism version 5.0c, (GraphPad Software, San Diego, CA, USA).6 PPAR Research
Table 1: Eﬀect of GW501516 treatment on body weight (g) and hepatic triglycerides (mg/g of liver) in nontransgenic, hPPARδ and
hPPARδΔAF2 mice.
Genotype Treatment Number
of mice
Starting weight
(g)a
Ultimate weight
(g)a P valueb Hepatic trigs
(mg/g) P value
Non-Tg Control 5 24.35 ±0.44 24.03 ±0.53 0.1592 9.68 ±1.18
hPPARδ Control 5 22.27 ±0.98 22.15 ±1.27 0.972 15.73 ±3.62 ns 0.152c
hPARδΔAF2 Control 5 22.02 ±1.03 21.96 ±1.18 0.8675 52.98 ±6.06 ∗∗∗0.0001c
Non-Tg GW 5 21.36 ±0.44 20.77 ±0.53 0.1962 22.66 ±2.31 ∗∗0.0011d
hPPARδ GW 5 21.78 ±0.98 18.4 ±1.27 ∗0.0179 47.53 ±6.24 ∗∗0.0024d
hPARδΔAF2 GW 5 21.97 ±1.03 22.14 ±1.18 0.5767 25.66 ±2.16 ∗∗0.0023d
Values are the means ± S.E.M.
aValues adjusted for sex.
bP value of weight diﬀerence (ultimate body weight minus initial body weight; paired t-test).
cP value of diﬀerence between level of hepatic triglycerides: non-Tg control versus transgenics control (unpaired t-test).
dP value of diﬀerence between level of hepatic triglycerides: control versus treated groups (unpaired t-test).
the hPPARδΔAF2 transgenic mice (Figures 3(b) and 3(c)).
Interestingly, Acox1 expression was signiﬁcantly increased in
mice expressing hPPARδΔAF2 compared to nontransgenic
mice in the absence of the PPARδ agonist. The increase
in Acox1 expression was lowered in the presence of PPARδ
agonist (Figure 3(c)), indicating agonist-induced repression
by hPPARδΔAF2 as described by Gustafsson et al. [26].
Adrp another PPAR target gene encodes a protein that
coats lipid droplets and is expressed during lipid accumu-
lation. Treatment of mice with GW501516 for 2 weeks leads
to up-regulation of Adrp mRNA in both liver and muscle of
nontransgenic mice (P = 0.008 for both organs). Again this
is most likely due to GW501516 activation of endogenous
mouse PPARδ (Figures 3(d) and 3(e)). In transgenic mice
expressing hPPARδ, there was an up-regulation of Adrp
by GW501516 in liver (P = 0.036) resulting in a 3.4-
fold activation. Nontransgenic animals displayed an iden-
tical (3.4-fold) activation of Adrp by GW501516 in their
livers (Figure 3(d)). Levels of Adrp were also increased by
GW501516 in the muscle of these animals but did not reach
signiﬁcance (P = 0.151) (Figure 3(e)). Thus, the extent of
basalandGW501516-inducedexpressionofAdrpinliverand
muscle do not seem to be aﬀected by hPPARδ transgene.
Interestingly, basal levels of Adrp were signiﬁcantly higher in
mice expressing hPPARδΔAF2 compared to either nontrans-
genic or hPPARδ transgenic counterparts on I3C diet (P =
0.016 for both organs) (Figures 3(d) and 3(e)). The ability
of hPPARδΔAF2 to repress expression of Adrp mRNA in the
presence of GW501516 was evident in both liver and muscle
of these animals with Adrp mRNA levels approaching the
basallevelsinnontransgenicandhPPARδ transgenicanimals
on I3C diet (Figure 3). This is most likely the result of
ligand-augmented repression by hPPARδΔAF2 described by
us previously [26]. Endogenous mouse PPARδ mRNA levels
showed no change in expression pattern between treatment
o rt r a n s g e n eg r o u p s( Figure 3(f)).
Treatment of hPPARδ mice with GW501516 led to a
greater than 200% increase in the accumulation of hepatic
triglycerides when compared to untreated hPPARδ animal
fed on control diet (P = 0.0024; Table 1).
Surprisingly, hPPARδΔAF2 animals fed on control diet
had liver triglycerides levels comparable to the hPPARδ mice
fed the ligand-supplemented diet. However, hPPARδΔAF2
animals treated with GW501516 had a lower level of hepatic
triglycerides (−108%), when compared to hPPARδΔAF2 fed
oncontroldiet(P = 0.0023;Table 1).Nontransgenicanimals
fed a diet supplemented with GW501516 displayed an
increased hepatic triglyceride levels (122%) when compared
to nontransgenic animals on control diet (P = 0.0011;
Table 1).
2.4. Expression of PPARδ and PPARδΔAF2 Modulate
Bezaﬁbrate-Induced Hepatomegaly. Bezaﬁbrate has been
shown to act as a dual PPARα/PPARδ agonist in mice and
to cause hepatomegaly when administered in the diet at
0.5% (w/w). This response is completely absent in PPARα
knockout mice [25]. To investigate whether or not PPARδ or
PPARδΔAF2 expression could modulate PPARα-dependent
hepatomegaly in mice fed with bezaﬁbrate, mice were placed
on a diet containing I3C (0.5% (w/w)) for 10 days to induce
PPARδ transgene expression. Following this, GW501516
(0.005% (w/w)), a PPARδ-speciﬁc ligand, or the PPARα/δ
dual ligand, bezaﬁbrate (0.5% (w/w), was introduced to
the diet containing I3C (0.5% (w/w)) for a further 10
days. Subsequently animals were sacriﬁced and liver weights
recorded. Nontransgenic mice showed a decrease in liver
weight (P = 0.032) when fed on GW501516-supplemented
diet (Figure 4(a)). In contrast, nontransgenic animals fed
bezaﬁbrate supplemented diet displayed an increase in liver
weight (P = 0.003) (Figure 4(a)). This ﬁnding is in
agreement with previously published data [25]. Animals
expressing hPPARδ or hPPARδΔAF2 showed no change in
liver weight when fed with either bezaﬁbrate or GW501516
containing diets (Figure 4(a)).
2.5.PPARδ andPPARδΔAF2ModulateBezaﬁbrateRegulation
of Gene Expression in the Liver. To investigate whether or
not the ability of hPPARδ and hPPARδΔAF2 to alleviate
bezaﬁbrate-induced hepatomegaly in these mice was associ-
atedwitharepressionofbezaﬁbrate-inducedgeneexpression
by the hPPARδ and hPPARδΔAF2 transgenes, we examined
mRNAexpressionfromtheliversofmicetreatedwithbezaﬁ-
brate or GW501516. The level of Acox1 in nontransgenic
mouse liver was strongly induced by bezaﬁbrate but not byPPAR Research 7
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Figure 4: Expression of hPPARδ and hPPARδΔAF2 abolish bezaﬁbrate-induced hepatomegaly in liver. Animals (n = 2–4 animals per group)
werefedadietcontainingI3C(0.5%(w/w))for10dayspriortobeingplacedondietscontainingI3C(0.5%(w/w))(Controldiet;openbars),
or a diet containing I3C (0.5% (w/w)) and GW501516 (0.005% (w/w)) (GW501516 diet; black bars) or a diet containing I3C (0.5% (w/w))
and bezaﬁbrate (0.5% (w/w)) (bezaﬁbrate diet; striped bars) for a further 10 days. (a) Liver weights of animals are expressed as a percentage
of body weight. (b) Liver Acox1 mRNA expression. Graphs were analysed using the Mann-Whitney non-parametric test in GraphPad Prism
version 5.0c, GraphPad Software, San Diego, California, USA. Signiﬁcance is indicated as (∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.001).
GW501516 (Figure 4(b)). In contrast, hPPARδ transgenic
mice displayed decreased constitutive levels of Acox1 (P =
0.003), but retained inducibility with both GW501516 and
bezaﬁbrate (P = 0.001 and P = 0.011, resp.). Taken
together, these observations suggest, that hPPARδ represses
basal expression of Acox1, and that GW501516 activated-
hPPARδ induces expression of Acox1 in the livers of these
animals(Figure 4(b)).ThelevelofAcox1 expressionachieved
by bezaﬁbrate in the hPPARδ transgenic mice was much
lower than that achieved in the nontransgenic animals (P =
0.0095). There were no signiﬁcant changes in the liver
expression levels of Acox1 in the hPPARδΔAF2 animals in
response to either GW501516 or bezaﬁbrate (Figure 4(b)).
Of note, even though the change was not statistically signif-
icant, we observed a trend to a ligand-dependent repression
of PPARδ target gene expression in hPPARδΔAF2 animals
similar to that observed in in vitro cellular assays [26]a n d
in (Figures 3(b)–3(e) and Figure 4(b)). These observations
provide further evidence for the dominant negative role of
the hPPARδΔAF2 transgene in regulating both GW501516
(PPARδ speciﬁc agonist) and bezaﬁbrate (PPARα/δ dual
agonist) gene induction in vivo (Figure 4(b)).
3. Discussion
Attempts to resolve PPARδ biology have proven diﬃcult
with several groups reporting contradictory results obtained
frombothgeneticandpharmaceuticalmodulationofPPARδ
activity [8, 19, 20]. We believe that the interpretation
of PPARδ experimentation results is confounded by the
ability of PPARδ to function as a repressor and activator
of transcription depending on ligand binding status. We
hypothesised that a more subtle modiﬁcation of PPARδ in
vivo would provide a useful tool to help delineate the
biology of this nuclear receptor. To that end, we have in
this study described two transgenic mouse models that
conditionally expresses either human PPARδ or a dominant
negative derivative of hPPARδ lacking the carboxy terminal
11 aminoacids comprising the activation function 2 domain
of the protein. Both transgenes are functional, and human
PPARδ mRNA is detectable in a range of tissues and protein
expressionisevidentintheliver(Figure 2).Inaddition,these
transgenic animals are refractory to bezaﬁbrate-induced
hepatomegaly (Figure 4) indicating that these mice are
synthesising functional human PPARδ protein in vivo.I n
other model of humanized mice generated by Gross et al.,
the endogenous murine PPARδ w a sr e p l a c e dw i t hh u m a n
PPARδ. Gene expression proﬁling in liver, soleus muscle,
and macrophages showed similar gene patterns regulated by
mouse and human PPARδ. In terms of regulation of lipid
metabolism and inﬂammation, authors indicate that human
PPARδ can compensate for mouse PPARδ [34].
The regulation of the rat Cyp1a1 gene is well charac-
terized and tightly controlled, and its promoter has been
used for the conditional expression of genes in transgenic
animals [28–30]. Our results demonstrate that expression of
hPPARδ and hPPARδΔAF2 is highly inducible in the liver
and intestine, but not in all tissues examined. For example,
thestomachdisplayedahighbasalexpression ofbothPPARδ
transgenes that was not signiﬁcantly induced by feeding I3C.8 PPAR Research
InskintherewasnosigniﬁcantinductionofmRNAforeither
transgene. However, administration of dietary GW501516 to
hPPARδ mice results in skin thickening with psoriasis-like
lesions. In the skin of hPPARδ mice, basal hPPARδ protein
is detected in the sebaceous gland. When exposed to I3C,
these animals show inducible PPARδ mRNA expression in
keratinocytes [32].
When the liver was examined for hPPARδ and
hPPARδΔAF2 protein expression, mRNA and protein levels
did not correlate well. In hPPARδ transgenic animals, there
was a clear hPPARδ protein signal that was not substantially
elevated above endogenous mouse PPARδ. In contrast,
hPPARδΔAF2 protein expression was very weak despite
a robust I3C-dependent increase in mRNA expression
(Figure 2). Notwithstanding this, the hPPARδΔAF2 protein
was clearly functional. In animals expressing hPPARδΔAF2,
there was a complete inhibition of PPARδ-mediated induc-
tion of Acox1 or Adrp in the liver and muscle in the presence
of the PPARδ agonist GW501516 (Figures 3(c), 3(d),a n d
3(e)).
One noticeable observation is the higher basal levels of
bothAcox1 inmuscleandAdrp inliverandmuscleofanimals
expressing hPPARδΔAF2 protein without an added PPARδ
agonist in the diet. This may be as a result of the nonliganded
dominant negative protein relieving endogenous mouse
PPARδ-dependent repression of these genes as suggested by
previous studies, particularly by the sequestration of RXR
species from PPARδ-RXR heterodimers leading to PPRE
being occupied by DR1 binding positive regulators that do
not require RXR such as HNF4 or COUP-TFII [35–37].
Further work is required to conﬁrm this at the genomic
level.
In contrast to nontransgenic mice, the levels of Acox1
and Adrp were actually reduced in the presence of PPARδ
agonist in the hPPARδΔAF2 mice when compared to the
levelsinanimalsnotreceivingGW501516.Thisisinlinewith
our previous observations where in vitro transfection experi-
ments suggested that the hPPARδΔAF2-mediated repression
is enhanced by a PPARδ agonist (most probably due to ago-
nist enhanced hPPARδΔAF2/RXR heterodimerisation and
thusincreasedPPREaﬃnity)[26].Thiscomplexrelationship
between ligand-activated and dominant negative PPARδ in
the control of gene expression reﬂects the ﬁndings of recent
genomewideexpressionandchromatinimmunopreciptation
studies by Adhikary et al., (2011), where diﬀering modes of
target gene regulation by PPARδ have been deﬁned. In these
studies,PPARδ wasshowntoelicit3diﬀeringtranscriptional
responses; (a) type 1 response: genes that were up-regulated
by siRNA knock down of PPARδ, but were not induced
by GW501516, (b) type II response: genes that were up-
regulated by knock down of PPARδ and could be up-
regulatedbyGW501516,and(c)typeIIIresponse:genesthat
are downregulated by PPARδ siRNA that then showed either
no response or a weak induction by GW501516 [38]. Ability
to repress the gene expression by PPARδ was also shown in a
study carried out by Kino et al.. In this work, overexpression
of PPARδ enhanced the suppressive eﬀect of GW501516 on
transcriptionalregulationofInterleukin-6[39].Theseobser-
vations support the complex interaction between activation
and expression of PPARδ and the regulation of speciﬁc gene
targets.
Ligand-activated hPPARδ did not increase mRNA levels
of Acox1 Adrp in muscle, or Adrp in liver over and above that
seen by endogenous ligand-activated mPPARδ (Figure 3).
In liver, hPPARδ mRNA and protein was up-regulated by
feeding I3C in the diet. In the case of liver, this resulted
in a ligand-dependent hPPARδ-speciﬁc activation of Acox1.
Acox1 wasnotinducedbyGW501516aloneinnontransgenic
livers, suggesting that endogenous mPPARδ does not aﬀect
Acox1 expression in the liver of these animals but does inﬂu-
ence Acox1 expression in the muscle (Figures 3(b) and 3(c)).
Adrp expression, on the other hand, is activated by ligand-
activated endogenous mouse PPARδ in both liver and mus-
cle, but not modulated by ligand-activated conditionally-
expressed human PPARδ in either of these organs. These
results may highlight species diﬀerences in PPARδ and how
it modulates gene expression diﬀerently depending on its
environment. Taken in context of the work carried out by
Adhikary et al. [38], PPARδ elicits a type II transcriptional
response in regulating Acox1 in mouse muscle and Adrp
in liver and muscle, but mouse PPARδ does not regulate
Acox1 in mouse liver. Interestingly Adhikary et al. note
that “the magnitude of induction by ligand approaches the
eﬀect of PPARδ depletion for individual genes showing a
type II response.” This is mirrored exactly in this model
system. The induction (or relief of repression) of muscle
Acox1 and liver and muscle Adrp mRNA observed in the
presence of hPPARδΔAF2 has a magnitude identical to the
induction observed in the presence of GW501516 (Figures
3(c), 3(d),a n d3(e)). Another striking observation in
removing the AF2 domain of PPARδ (PPARδΔAF2) results
in certain target genes being transcriptionally activated a
similar manner to treatment of wild-type mice by the PPARδ
ligand GW501516. The opposite is also true, hPPARδΔAF2
activated by GW501516 results in gene expression levels
identical to those seen in hPPARδ transgenic animals in
the absence of GW501516 (Figures 3(c), 3(d),a n d3(e)).
Thereisnoevidencethathepaticlevelsofendogenousmouse
PPARδ mRNA are being aﬀected by transgene induction or
GW501516 treatment (Figure 3(f)). PPARδ is known to be
induced by exercise, fasting, and other factors rather than by
self-activation [40].
PPARδ hasaroleinenergyhomeostasisasakeyregulator
of fatty acid oxidation, is expressed in skeletal muscle,
with a higher expression in soleus muscle. Soleus muscle
consists of fatigue resistant type 1 muscle ﬁbres that have
a high mitochondria content and use oxidative metabolism
for energy production. Activation of PPARδ is known to
promote weight loss [15, 33] that was particularly evident
whenhPPARδ animalswerefedadietcontainingGW501516
(Figure 3). Interestingly, the increased weight loss seen in the
mice expressing hPPARδ cannot be a strictly muscle eﬀect in
these mice, as hPPARδ was not induced in muscle of these
animals (Figure 2(c)).
So far, role of PPARδ in promoting or preventing hepatic
steatosis is an open question [14, 41]. In nontransgenic
mice, 2 weeks of PPARδ ligand treatment caused only mod-
erate (2-fold) ﬂuctuations in liver triglycerides (Table 1),PPAR Research 9
whereas in human PPARδ transgenic mice, two weeks of
GW501516 treatment was suﬃcient to cause a signiﬁcant
accumulation of hepatic triglycerides (Table 1). A higher
level of triglycerides was also found in livers of hPPARδΔAF2
animals on control diet, but not in hPPARδΔAF2 mice
fed with a GW501516-supplemented diet. This role of the
dominant negative enabling a “reverse agonism” action of
GW501516 was ﬁrst seen in our in vitro work, and it is
intriguing that it is seen so clearly with the hepatic lipid
accumulation as well as the target gene expression. This
mechanismofthisregulationofhepatictriglycerideaccumu-
lation is not clear and requires further investigation.
It is not unusual for PPARs to behave diﬀerently across
species. PPARα is employed as a successful target for phar-
maceutical intervention in humans with ﬁbrate drugs
being important in treatment of dyslipidemia and cardio-
vascular disease [42]. In rodents, however, ﬁbrate drugs
cause hepatomegaly and eventually hepatic carcinoma [2],
which is not seen in humans, and is reﬂected in a much
lower level of expression of PPARα and thus a diﬀerent
balance between PPARα and PPARδ in the human liver
[4]. This interaction between PPARα and PPARδ levels
in the regulation of hepatomegaly was borne out by
our observation that bezaﬁbrate-induced hepatomegaly was
blockedbyhPPARδΔAF2.Inaddition,expressionofhPPARδ
blocked bezaﬁbrate-dependent hepatomegaly and modu-
lated bezaﬁbrate-dependent gene expression. Taken together,
thisdatademonstratesthatunligandedPPARδ can,incertain
circumstances, inhibit the action of PPARα.
In summary, there have been many conﬂicting and
confusing studies attempting to understand PPARδ biology
in vivo, which are complicated by PPARδ being able to
both repress and activate gene expression. Genetic models of
deleting PPARδ have been very insightful for elucidating the
biology of this nuclear receptor. By conditionally expressing
hPPARδ and hPPARδΔAF2 in an otherwise normal endoge-
nous mouse PPARδ background, we sought to generate
animal models that would allow a more subtle examination
of PPARδ biology without the complication of removing or
inactivating a protein with a dual function. These animals
will provide a useful tool to complement studies with
knockout and drug models to help resolve the confusing
results in the literature regarding PPARδ biology.
4.MaterialsandMethods
4.1. Reagents. All chemicals used were of the highest grade
available and were, unless otherwise stated, purchased from
Sigma/Aldrich, Gillingham, Dorset, UK. GW501516 was
synthesised by AF ChemPharm Ltd., Sheﬃeld, UK.
4.2. Transgenic Mouse Generation. Throughout this study all
animals were treated in accordance with regulations con-
tainedintheAnimalsandScientiﬁcProceduresAct(1996)of
the United Kingdom, and with the approval of the University
of Dundee ethical committee. Mice were housed in an
environment with a temperature range of 19–23◦C, under 12
hourlight/darkcyclesandgivenfreeaccesstofoodandwater.
The animals were fed with RM1 laboratory animal feed (SDS
Ltd., Wickam, UK).
The generation of mice expressing hPPARδ is described
elsewhere [32]. To generate mice conditionally over-ex-
pressing a derivative of hPPARδ lacking the eleven carboxy-
terminal aminoacids residues (hPPARδΔAF2) [26, 27], the
coding sequence of hPPARδ was ampliﬁed using primer
PRMG15 (5 -CTAGTCTAGAATGGAGCAGCCACAGGAG-
GAAGC-3 )a n dP R M G 1 6( 5  -CTAGTCTAGATTAGTG-
CAGCGAGGTCTCGGTTTC-3 ), (XbaI-sites underlined,
ATG start codon in bold). This PCR product was cleaved
with XbaI and cloned into plasmid pUHD10-3 (M. Gossen,
unpublished, Genbank accession number U89931) creating
pMGD10. The integrity of the insert ion was conﬁrmed
by sequencing and cleaved out using BamHI and ligated
into pAHIR1-β-gal [28], digested with BglII resulting in
plasmid pMGD18 (hPPARδΔAF2). The correct orientation
was conﬁrmed by sequencing. Mice were generated as for
hPPARδ asdescribedpreviously[32].Fourfounderlinesona
C57BL/6 background were generated for each transgene and
analysed for induction of transgene expression and suitable
lines selected and brought forward for experimental analysis.
Forexperimentalanalysis,allanimalswerebetween8and
12 weeks of age. See ﬁgure legends of individual experiments
for numbers and sex of the animals included.
Transgene expression was induced by supplementing the
feed with indole 3-carbinol (I3C) at either 0.5% or 0.25%
(w/w). Activation of hPPARδ andhPPARDδΔAF2 transgenes
intheseanimalswasachievedbysupplementingthedietwith
bezaﬁbrate (0.5% w/w) or GW501516 (0.005% or 0.0025
w/w). See ﬁgure legends of individual experiments for exact
dietary supplementation and time frames.
4.3. Determination of Transgene Detection. All animals were
analysed for the presence of the transgene by PCR. DNA
was extracted from ear notches and the hPPARδ or
hPPARδΔAF2 transgene was ampliﬁed using primer set
PRMG159 (5 -CCAACCACCCTGTCCCAGCTTG-3 )a n d
PRMG160 (5 -ACAAACTCTGCCCTGCTCTATG-3 ) using
HotStarTaq DNA polymerase and Q-solution (Qiagen).
4.4. RNA Isolation and Semiquantitative Real-Time PCR.
Total RNA from mouse tissue was isolated using the RNeasy
Mini Kit (Qiagen) from kidney, liver, spleen, lung, ovary, and
testis. The RNeasy Lipid kit (Qiagen) was used to isolate total
RNA from brain, adipose, and breast. Total RNA isolation
from heart, muscle, large and small intestines, stomach, and
skinwasisolatedusingRNeasyMiniFibrouskit(Qiagen).All
tissue samples were snap frozen in liquid N2 upon harvest
and kept frozen until homogenization in the relevant RNA
extraction kit buﬀers using a rotor-stator homogenizer. RNA
isolation kits were used as per manufacturer’s instructions,
and in all cases an on-column DNAse digestion step was
included prior to total RNA elution to ensure complete
removal of any genomic DNA from the preparation. Puriﬁed
total RNA was stored at −80◦C. First strand cDNA synthesis
form 200ng of RNA was performed using Omniscript
Reverse Transcription kit (Qiagen). Upon completion, the10 PPAR Research
reaction was diluted in water, and a volume representing
5ng of starting material was used for PCR reactions. The
measurement of mRNA levels was achieved using quantita-
tive real-time PCR using TaqMan chemistry on an Applied
Biosystems 7900 sequence detector instrument. The primer
and probe sets used to amplify hPPARδ were published
previously [43]. The primer and probe set used to amplify
mouse Acox1mRNA was primer: 5 -TGACCGTTAAGG-
TCTTTGCAGA-3  and 5 -AGGTTCCTCAGCACGGCTT-
3  with probe 5 -[Fam]-AACTCCCCAAGATTCAAGACA-
GAGCCGT-[Tamra]-3 .M o u s eAdrp mRNA was ampliﬁed
using primer 5 -CAGCCAACGTCCGAGATTG-3  and 5-
CACATCCTTCGCCCCAGT-3 ;p r o b e5  [FAM]-TGCCAG-
TGCCAGAGGTGCCGT-[Tamra]-3 .
4.5. Lipid Measurements. Total hepatic lipids were extracted
according to Folch method [44]. Lipid analysis of liver
extracts was performed using RX Daytona clinical analyser
(Randox, UK) following manufacturer’s instructions.
4.6. Western Blot. Soluble lysates were prepared from frozen
liver as described previously [45]. Protein concentrations
were determined by the Bradford dye-binding assay (Bio-
Rad). For immunoblotting, 30μg aliquots of liver lysate were
resolved by SDS/polyacrylamide-gel electophoresis, trans-
ferred to immobilon-P membranes and blocked with recon-
stituted dried milk (10% w/v) in TBS-tween. Membranes
were probed with antihuman PPARδ/NR1C2 monoclonal
antibody (R&D systems) at a concentration of 1μg/mL in
TBS-tween supplemented with dried milk powder (10%
(w/v)). Following washing the membrane was incubated
with secondary antimouse IgG coupled to horseradish per-
oxidase (1:10,000 dilution) (Dako). Bands were visualized
using enhanced chemiluminescence (Millipore), and images
were captured using the Fujiﬁlm LAS3000 mini imager. To
conﬁrm equal loading of samples, blots were reprobed with
antibodies against GAPDH (Sigma).
4.7. Statistical Analysis. Data was analysed using GraphPad
Prism Software (Graphpad Software Inc., CA, USA). Statis-
tical signiﬁcance was calculated using the non-parametric
Mann-Whitney U test. Statistical signiﬁcance is described
in the text and is indicated in the ﬁgures as (
∗P ≤ 0.05;
∗∗P ≤ 0.01;
∗∗∗P ≤ 0.001).
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